clinical trial · NCT07049432
N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
B-cell Non Hodgkin LymphomaN803
brief summary
The purpose of this clinical trial is to learn whether the study drug N-803 is safe and tolerable in patients with B-cell non-Hodgkin lymphoma who have undergone CAR T-cell therapy.
started
Feb 1, 2026
primary completion
Dec 1, 2030
completion
Dec 1, 2031
last updated
Apr 1, 2026
official title
A Phase I Study of N-803 Maintenance Therapy Following CD19 Directed CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (CARMEN-803 Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol